A secondary RET mutation in the activation loop conferring resistance to vandetanib

Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. The resistant tumor acquired a secondary mutation resulting in a serine-to-phenylalanine substitution at...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaoku, Takashi, Kohno, Takashi, Araki, Mitsugu, Niho, Seiji, Chauhan, Rakhee, Knowles, Phillip P., Tsuchihara, Katsuya, Matsumoto, Shingo, Shimada, Yoko, Mimaki, Sachiyo, Ishii, Genichiro, Ichikawa, Hitoshi, Nagatoishi, Satoru, Tsumoto, Kouhei, Okuno, Yasushi, Yoh, Kiyotaka, McDonald, Neil Q., Goto, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809600/
https://www.ncbi.nlm.nih.gov/pubmed/29434222
http://dx.doi.org/10.1038/s41467-018-02994-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809600/
https://www.ncbi.nlm.nih.gov/pubmed/29434222
http://dx.doi.org/10.1038/s41467-018-02994-7

Ejemplares similares